



If antihistamines alone aren't enough, ask your health care provider about

**The ONE
and ONLY***

RHAPSIDO[®]
(remibrutinib)

*Treatment that targets inside the mast cell, helping to inhibit some histamine release.

CSU, chronic spontaneous urticaria;
SD, symptomatic dermographism.

CSU patient portrayal.

Approved Uses

What is RHAPSIDO[®] (remibrutinib)?

RHAPSIDO is a prescription medicine used to treat adults with chronic spontaneous urticaria (CSU) or symptomatic dermographism (SD) who continue to have symptoms that are not controlled with antihistamine treatment. It is not known if RHAPSIDO is safe and effective in children.

Important Safety Information

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you:

- Have had a recent surgery or plan to have surgery. Your health care provider may tell you to stop taking RHAPSIDO for at least 3 to 7 days before and after any planned medical or surgical procedures

Please see Important Safety Information throughout and the [Important Facts about RHAPSIDO](#).

Rhapsido
(remibrutinib) 25mg tablets

04

About Chronic Spontaneous Urticaria and Symptomatic Dermographism

→

06

Results With RHAPSIDO® (remibrutinib)

→

12

How RHAPSIDO Works

→

14

Safety Overview

→

16

How to Start and Stay on RHAPSIDO

→

18

Hear From Real Patients

→

20

Support and Resources

→

22

Talking to Your Health Care Provider

→



CSU patient portrayal.

What are the 2 most common types of chronic hives?

CSU

Chronic spontaneous urticaria (CSU), or chronic hives with no known external triggers

CSU symptoms may include raised, itchy hives, swelling or both that last more than 6 weeks.

SD

Symptomatic dermographism (SD), or chronic hives from scratching or rubbing on the skin

Symptoms may include red, raised, itchy hives that appear within minutes of friction on the skin, from everyday things like clothing or even rubbing from a seat belt.



What makes them chronic?

When symptoms come and go for more than 6 weeks, it's considered chronic hives. Like other chronic conditions, management may require ongoing treatment, even if symptoms improve.



How are CSU and SD treated?

Antihistamines are the first line of treatment to help manage CSU and SD, but for about 1 in 2 people, antihistamines alone may not be enough.



CSU patient portrayal.



Pill not
actual size.

When antihistamines alone aren't enough, **RHAPSIDO® (remibrutinib)** is the **first-and-only* twice-daily oral prescription pill approved to treat both CSU and SD**

*Treatment that targets inside the mast cell, helping to inhibit some histamine release.

Important Safety Information (cont)

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you: (cont)

- Have bleeding problems or are taking a blood thinner medicine
- Have liver problems

CSU**Chronic spontaneous
urticaria (CSU)**

Fast relief from hives and itch measured at week 12

In one clinical study

Weekly hives severity score (HSS7) dropped
10.47 points with RHAPSIDO vs 6.00 with placebo
on average from the start of the study.

70% reduction in
HIVES
vs 39% with placebo*

Weekly itch severity score (ISS7) dropped
8.95 points with RHAPSIDO vs 5.72 with placebo
from the start of the study.

67% reduction in
ITCH
vs 42% with placebo*

*These results were calculated from observed data. No statistical analyses were done and conclusions should not be drawn.

Results seen
as early as **week 2**

**~5x as many people had
WELL-CONTROLLED HIVES AND ITCH**
weekly urticaria activity score (UAS7 ≤ 6) with
RHAPSIDO (30% vs 5.9% with placebo) at week 2.

How results were tested in clinical trials

RHAPSIDO was studied in 2 identical clinical trials in adults (≥ 18 years of age) with CSU who continued to have symptoms while taking antihistamines. **All participants stayed on antihistamines** while also taking either RHAPSIDO twice daily for a year or placebo (in the trial presented: RHAPSIDO, n=297; placebo, n=153). Placebo does not contain any active medicine. Results were similar between both trials.

Important Safety Information (cont)

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you: (cont)

- Are pregnant or plan to become pregnant. It is not known if RHAPSIDO will harm your unborn baby. If you become pregnant during treatment with RHAPSIDO, talk to your health care provider about registering in the pregnancy exposure registry for RHAPSIDO
- Are breastfeeding or plan to breastfeed. It is not known if RHAPSIDO passes into your breast milk
- Have recently received or are scheduled to receive an immunization (vaccine). Talk to your health care provider about receiving any immunizations before taking RHAPSIDO. You should not receive live or live-attenuated vaccines during treatment with RHAPSIDO

For more information about results, visit [RHAPSIDO.com](https://rhapsido.com).

CSU

Chronic spontaneous urticaria (CSU)

Measuring hives and itch relief

Hives and itch were measured using 3 established scales. Participants rated their hives and itch twice a day from 0 to 3, with higher scores indicating more severe symptoms. The average daily ratings were added up each week and compared to their starting scores.

HSS7 (Weekly hives severity score)	Measures the number of hives for a week (score ranging from 0 to 21).
ISS7 (Weekly itch severity score)	Measures itch intensity for a week (score ranging from 0 to 21).
UAS7 (Weekly urticaria activity score)	Combines both hives and itch scores to reflect the total weekly severity of symptoms (score ranging from 0 to 42). The total can range from 0 to 42, 0 is complete absence of hives and itch, 1-6 is well-controlled, 7-15 is mild, 16-27 is moderate, and 28-42 is severe.

Important Safety Information (cont)

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking RHAPSIDO with certain other medications may affect how RHAPSIDO or your other medications work and can cause side effects.



Not an actual CSU patient or health care professional.

SD**Symptomatic
dermographism (SD)**

Fast and complete response from hives based on TFS measured at week 12

In the clinical study

~2x as many people were
HIVE-FREE

defined as achieving a TFS of 0 at 12 weeks,
29.3% had complete response from hives
compared with 14% taking a placebo.

Results seen
as early as **week 2**

~3x as many people were **HIVE-FREE**

defined as achieving a TFS of 0 at 2 weeks,
29.3% had complete response from hives
compared with 8.8% taking a placebo.

TFS, Total Fric Score.

Important Safety Information (cont)

What are the possible side effects of RHAPSIDO?

RHAPSIDO may cause serious side effects, including:

- **Risk of bleeding.** Bleeding may happen while being treated with RHAPSIDO. Your health care provider will monitor you for signs and symptoms of bleeding and may stop your treatment if bleeding happens. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your health care provider right away if you get any signs or symptoms of bleeding, such as:
 - Bruising or red or purple skin marks
 - Pink or brown urine
 - Headache, dizziness, confusion, or feeling weak
 - Red or black stools that look like tar

Reduction in most bothersome symptom (MBS) score at week 12

At the start of the study, people identified their most bothersome SD symptom by selecting between itch, burning, or pain. Their individually chosen symptom was then tracked throughout the study.

Weekly MBS score was reduced an average of 1.96 points with RHAPSIDO vs 0.33 points with placebo compared to the start of the study.

How results were tested in clinical research

RHAPSIDO was studied in adults (≥18 years of age) with SD who continued to have symptoms while taking antihistamines. **All participants stayed on antihistamines** while also taking either RHAPSIDO or placebo (RHAPSIDO, n=58; placebo, n=57). Placebo does not contain any active medicine.

Explanation of how data were evaluated

Total Fric Score (TFS): Measures how the skin responds in number of hives seen after it has been scratched or rubbed with the FricTest® (score ranging from 0 to 4). A Fric test uses a 4-prong tool that applies pressure to the skin, to induce hives in patients with SD.


Weekly most bothersome symptom (MBS) score:

Measures the MBS for a week (score ranging between 0 and 10).

For more information about results, visit [RHAPSIDO.com](https://rhapsido.com).


RHAPSIDO offers a different approach

How RHAPSIDO is believed to work



Overactive immune system

Chronic spontaneous urticaria (CSU) and symptomatic dermographism (SD) can occur when your immune system becomes overactive.




Histamine release

When this happens, a signal causes mast cells to release histamine.



Symptoms

Histamine may cause itching, redness, and/or swelling.



RHAPSIDO targeted action in the mast cell

RHAPSIDO is the only pill of its kind that targets inside the mast cell, helping to inhibit some histamine release.

How RHAPSIDO works in the body and how it affects your symptoms are unknown.



CSU patient portrayal.

Important Safety Information (cont)

The most common side effects with RHAPSIDO may include nasal congestion, sore throat, and runny nose (nasopharyngitis), bleeding, headache, nausea, and abdominal pain.

These are not all the possible side effects of RHAPSIDO.

RHAPSIDO® (remibrutinib) has a proven safety profile

CSU

Chronic spontaneous urticaria

The safety of RHAPSIDO was studied in the largest clinical trials for adults living with CSU and was evaluated at 6 months (868 patients).*

*Based on completed trials for CSU as of September 2025.

The most common side effects seen in clinical trials for CSU

- **Nasopharyngitis**

(nasal congestion, sore throat, and runny nose)

11% of those who took RHAPSIDO and

9% who took placebo

- **Headache**

7% of those who took RHAPSIDO and

6% who took placebo

- **Nausea**

3% of those who took RHAPSIDO and

2% who took placebo

- **Abdominal Pain**

3% of those who took RHAPSIDO and

2% who took placebo

View the full [Prescribing Information](#) to learn more.

Important Safety Information (cont)

Call your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.



CSU patient portrayal.

- **Bleeding**

9% of those who took RHAPSIDO and
2% who took placebo

- In the CSU clinical trials, of the 9%, the most common were tiny red spots beneath the skin (4%)

- Occurred within the first 3 months of treatment

- Mostly seen on the arms, legs, neck, or stomach

- 1 patient (0.2%) in the RHAPSIDO group and no patients in the placebo group stopped treatment

SD Symptomatic dermographism

The safety profile of RHAPSIDO in the SD trial was consistent with the safety profile in the CSU trials.

NOT an antihistamine.
NOT a steroid. **NOT** an injection.

Patient portrayal;
pill not actual size.

Experience RHAPSIDO

Pair RHAPSIDO with your daily schedule

An example of how you can take RHAPSIDO is during your morning wake-up routine and your evening wind-down. How you take RHAPSIDO is up to you, as long as you take it as prescribed twice-daily, even if symptoms come and go.

Remember that chronic means the condition is long term

Keep taking RHAPSIDO exactly as prescribed until your health care provider tells you to stop.


The recommended dose of RHAPSIDO is 25 mg twice daily

If a dose of RHAPSIDO is missed, it should be skipped, and the next dose should be taken at its regularly scheduled time. You should not take extra doses to make up for a missed dose or doses.

For full dosing information, see the RHAPSIDO [Prescribing Information](#).

Rhapsido
(remibrutinib) 25mg tablets

Share your story



Lauren, a real patient living with CSU

If you or a loved one is taking **RHAPSIDO**, consider sharing your story.

[Download](#)  for more information or visit www.RHAPSIDO.com.

Approved Uses

What is RHAPSIDO® (remibrutinib)?

RHAPSIDO is a prescription medicine used to treat adults with chronic spontaneous urticaria (CSU) or symptomatic dermographism (SD) who continue to have symptoms that are not controlled with antihistamine treatment. It is not known if RHAPSIDO is safe and effective in children.

Please see Important Safety Information throughout and the [Important Facts about RHAPSIDO](#).

See what real patients are saying about taking RHAPSIDO® (remibrutinib)

Meet Lauren from Texas

“My daily routines are important. That’s why I take each dose of RHAPSIDO around the same time each day.

Lauren, a real patient living with CSU. Lauren was compensated for her time.



Important Safety Information

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you:

- Have had a recent surgery or plan to have surgery. Your health care provider may tell you to stop taking RHAPSIDO for at least 3 to 7 days before and after any planned medical or surgical procedures

CSU, chronic spontaneous urticaria; SD, symptomatic dermographism.

Rhapsido 
(remibrutinib) 25mg tablets

Meet Hannah from Pennsylvania

“Talking with my doctor about what I was going through was an important step in finding a treatment that was right for me.

Hannah, a real patient living with CSU. Hannah was compensated for her time.



Ready to take the next step?
Learn more at RHAPSIDO.com.

Are you living with CSU or SD?

Talk with your health care provider to find out if RHAPSIDO might be right for you.

Please see Important Safety Information throughout and the **Important Facts about RHAPSIDO**.

Get the support you need

Your RHAPSIDO® prescription may be filled through a specialty pharmacy. Before it ships, there are a few steps to complete. Novartis Patient Support is here to help.

Your Novartis Patient Support team

With Novartis Patient Support, you'll have a team you can count on who will reach out from the start and get to know you. When you have questions, you can talk to them directly.*

Sign up at www.support.RHAPSIDO.com



Financial support

Learn about savings and other possible ways to afford your treatment.



Insurance support

Navigate the insurance process and understand your insurance coverage information.



Ongoing support

Get helpful resources and answers to your questions throughout your treatment.

\$0

Co-Pay Plus^{offer†}

Eligible patients may pay as little as \$0 for RHAPSIDO



CSU patient portrayal.

Novartis Patient Support is not a clinical service and does not replace guidance from your health care provider. Our goal is to help you feel informed about your treatment from day one.



Scan or visit www.RHAPSIDO.com for support

*Novartis Patient Support does not provide clinical advice and is not a substitute for consulting with your health care provider.

†Limitations apply. Valid only for those with private insurance. The Program includes the Co-Pay Plus offer, Plus Card (if applicable), and Rebate, with a combined annual limit. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited toward patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

my hives & itch Tracker

Get ready for your next appointment by keeping a record of your symptoms.

[Download](#)



Not an actual CSU patient or health care professional.

Important Safety Information (cont)

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you: (cont)

- Have bleeding problems or are taking a blood thinner medicine
- Have liver problems
- Are pregnant or plan to become pregnant. It is not known if RHAPSIDO will harm your unborn baby. If you become pregnant during treatment with RHAPSIDO, talk to your health care provider about registering in the pregnancy exposure registry for RHAPSIDO

Ready to discuss next steps?

You don't have to manage your diagnosis alone. Your appointments are a chance to share what you're experiencing and how you're feeling, so you and your health care provider can make a treatment plan together.

These tips can support your next conversation



Track ongoing symptoms

Note when your symptoms happen, as well as intensity and duration. Consider whether your current treatment plan is helping. Take pictures to track progress and share with your health care provider.



Leave nothing out

Tell your health care provider about any treatment options you're taking or have tried, including prescription and over-the-counter medicines.



Advocate for yourself

If antihistamines alone are not providing enough symptom relief, talk with your health care provider to see if RHAPSIDO® (remibrutinib) is right for you.

Important Facts about RHAPSIDO

What is RHAPSIDO® (remibrutinib)?

RHAPSIDO is a prescription medicine used to treat adults with chronic spontaneous urticaria (CSU) or symptomatic dermatographism (SD) who continue to have symptoms that are not controlled with antihistamine treatment. It is not known if RHAPSIDO is safe and effective in children.

Important Safety Information

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you:

- Have had a recent surgery or plan to have surgery. Your health care provider may tell you to stop taking RHAPSIDO for at least 3 to 7 days before and after any planned medical or surgical procedures
- Have bleeding problems or are taking a blood thinner medicine
- Have liver problems
- Are pregnant or plan to become pregnant. It is not known if RHAPSIDO will harm your unborn baby. If you become pregnant during treatment with RHAPSIDO, talk to your health care provider about registering in the pregnancy exposure registry for RHAPSIDO
- Are breastfeeding or plan to breastfeed. It is not known if RHAPSIDO passes into your breast milk
- Have recently received or are scheduled to receive an immunization (vaccine). Talk to your health care provider about receiving any immunizations before taking RHAPSIDO. You should not receive live or live-attenuated vaccines during treatment with RHAPSIDO

Tell your health care provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking RHAPSIDO with certain other medications may affect how RHAPSIDO or your other medications work and can cause side effects.

What are the possible side effects of RHAPSIDO?

RHAPSIDO may cause serious side effects, including:

- **Risk of bleeding.** Bleeding may happen while being treated with RHAPSIDO. Your health care provider will monitor you for signs and symptoms of bleeding and may stop your treatment if bleeding happens. Your risk of bleeding may increase if you are also taking a blood thinner medicine. Tell your health care provider right away if you get any signs or symptoms of bleeding, such as:
 - Bruising or red or purple skin marks
 - Pink or brown urine
 - Headache, dizziness, confusion, or feeling weak
 - Red or black stools that look like tar

The most common side effects with RHAPSIDO may include nasal congestion, sore throat, and runny nose (nasopharyngitis), bleeding, headache, nausea, and abdominal pain.

These are not all the possible side effects of RHAPSIDO.

Call your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This information is not comprehensive.

To learn more, talk to your health care provider or visit www.rhapsido.com to obtain the FDA-approved product labeling.

RHAPSIDO® is the
FIRST-AND-ONLY*
oral prescription pill approved in CSU and SD
when antihistamines alone aren't enough

NOT an antihistamine. **NOT** a steroid. **NOT** an injection.



Pill not actual size.

Talk to your health care provider and ask if twice-daily
RHAPSIDO is right for you.

*Treatment that targets inside the mast cell,
helping to inhibit some histamine release.

CSU, chronic spontaneous urticaria;
SD, symptomatic dermographism.

Approved Uses

What is RHAPSIDO® (remibrutinib)?

RHAPSIDO is a prescription medicine used to treat adults with chronic spontaneous urticaria (CSU) or symptomatic dermographism (SD) who continue to have symptoms that are not controlled with antihistamine treatment. It is not known if RHAPSIDO is safe and effective in children.

Important Safety Information

Before taking RHAPSIDO, tell your health care provider about all of your medical conditions, including if you:

- Have had a recent surgery or plan to have surgery. Your health care provider may tell you to stop taking RHAPSIDO for at least 3 to 7 days before and after any planned medical or surgical procedures


Rhapsido®
(remibrutinib) 25mg tablets

Learn more at
www.RHAPSIDO.com

[Terms of Use](#) [Privacy Policy](#)



Follow RHAPSIDO
on social media for
information and updates

Please see Important Safety Information throughout
and the [Important Facts about RHAPSIDO](#).

 NOVARTIS

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

© 2026 Novartis

10/26

FA-11623637